Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000667051 | SCV000791442 | likely pathogenic | Bardet-Biedl syndrome 1 | 2017-05-16 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001060606 | SCV001225306 | pathogenic | Bardet-Biedl syndrome | 2024-02-01 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg440*) in the BBS1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BBS1 are known to be pathogenic (PMID: 12118255, 21520335, 27032803). This variant is present in population databases (no rsID available, gnomAD 0.006%). This premature translational stop signal has been observed in individual(s) with Bardet-Biedl syndrome (PMID: 12524598). ClinVar contains an entry for this variant (Variation ID: 551887). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV000667051 | SCV005054663 | pathogenic | Bardet-Biedl syndrome 1 | 2024-03-27 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000667051 | SCV002094766 | pathogenic | Bardet-Biedl syndrome 1 | 2021-03-18 | no assertion criteria provided | clinical testing |